Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

← catalyst calendar

NCT04784715 · readout in 84 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

1,157actual

Sites

283

Countries

Argentina, Belgium, Brazil +24

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-04-26

actual

When the study began enrolling

Primary completion

2026-11-11

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-12-30

estimated

The whole study's end, after follow-up

First posted

2021-03-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Breast Cancer; HER2-positive; Metastatic

Interventions

Drug: Trastuzumab deruxtecan — also filed as DS-8201a; T-DXd
Drug: Placebo
Drug: Taxane
Drug: Pertuzumab
Drug: Trastuzumab

Primary outcome

what the primary-completion date above is the date OF

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment

measured Until progression or death, assessed up to approximately 60 months

Publications

PMID 41160818 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed